Business
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\nFLEMINGTON, N.J., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data from a preclinical study demonstrating AR-13, an analogue of the Company's AR-12 infectious disease compound portfolio, has promise as a potential new therapeutic option for patients with cystic fibrosis (CF) acutely and chronically infected with Burkholderia cenocepacia and other antibiotic resistant organisms such as Pseudomonas aeruginosa. \n\n\tThe dataset will be presented in a poster session during the upcoming 29th Annual North American Cystic Fibrosis (NACF) Conference, being held October 8-10, 2015 in Phoenix, AZ.  \n\n\tAbstract #319 – AR-13 as a potential new therapeutic for reducing Burkholderia Cenocepacia burden in CF macrophages                      \n\n\t\n\t\t\n\t\t\t\n\t\t\t\tPoster Session:\n\t\t\t\n\t\t\t\tMain Poster session\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tDate, Time:\n\t\t\t\n\t\t\t\tThursday, October 8; 11:50 a.m. - 1:50 p.m. MT\n\t\t\n\t\t\n\t\t\t\n\t\t\t\t \n\t\t\t\n\t\t\t\tSaturday, October 10, 7:30 a.m. - 8:45 a.m. MT\n\t\t\n\t\t\n\t\t\t\n\t\t\t\t \n\t\t\t\n\t\t\t\tAlso available as an e-poster\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tLocation: \n\t\t\t\n\t\t\t\tHall CDE, Phoenix Convention Center in the main Exhibit Hall\n\t\t\n\t\n\n\n\tTHP-1 monocyte cell line, human peripheral blood samples containing monocyte derived macrophages and neutrophils from patients with CF and blood samples from non-CF healthy controls were used for this preclinical study.\n\n\tResults demonstrate that AR-13 in combination with broad-spectrum antibiotics has synergistic effects on reducing antibiotic-resistant B. cenocepacia burden in human CF macrophages. AR-13 alone also significantly reduces the CF pathogen Pseudomonas aeruginosa burden in CF neutrophils – specifically, a 70% reduction in P. aeruginosa burden in CF neutrophils and 66% reduction in non-CF neutrophils using AR-13 alone.  \n\n\tBenjamin T. Kopp, MD, Assistant Professor, Department of Pediatrics at The Research Institute at Nationwide Children's Hospital, commented, \"The ...